Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/125010
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease
Author: Golledge, J.
Rowbotham, S.
Velu, R.
Quigley, F.
Jenkins, J.
Bourke, M.
Bourke, B.
Thanigaimani, S.
Chan, D.
Watts, G.
Citation: Journal of the American Heart Association, 2020; 9(6):e015355
Publisher: Wiley
Issue Date: 2020
ISSN: 2047-9980
2047-9980
Statement of
Responsibility: 
Jonathan Golledge, Sophie Rowbotham, Ramesh Velu, Frank Quigley, Jason Jenkins ... Shivshankar Thanigaimani ... et al.
Abstract: Background: The aim of this study was to assess the relationship between serum lipoprotein (a) (Lp[a]) concentration and the requirement for peripheral artery disease (PAD) operations or incidence of major adverse cardiovascular events. Methods and Results: A total of 1472 people with PAD presenting with intermittent claudication (n=355), abdominal aortic aneurysm (n=989) or critical limb ischemia (n=128) were prospectively recruited from 4 outpatient clinics in Australia. Lp(a) was measured in serum samples collected at recruitment using an immunoassay. Participants were followed for a median (interquartile range) of 2.4 (0.1–6.1) years to record requirement for any PAD operation, defined to include any open or endovascular PAD intervention (lower limb peripheral revascularization, abdominal aortic aneurysm repair, other aneurysm repair, or carotid artery revascularization). Myocardial infarctions, strokes, and deaths were also recorded. The association of Lp(a) with events was assessed using Cox proportional hazard analysis adjusting for traditional risk factors. Participants with Lp(a) ≥30 mg/dL had a greater requirement for any PAD operation (hazard ratio, 1.20, 95% CI, 1.02–1.41) and lower limb peripheral revascularization alone (hazard ratio 1.33, 95% CI, 1.06–1.66) but no increased risk of major adverse cardiovascular events or all‐cause mortality. Lp(a) ≥50 mg/dL and a 40 mg/dL increase in Lp(a) were also associated with an increased risk of lower limb peripheral revascularization alone but not with other outcomes. Conclusions: In participants with PAD referred for hospital management those with high Lp(a) had greater requirement for lower limb peripheral revascularization but Lp(a) was not consistently associated with other clinical events.
Keywords: Surgical treatment; lipoprotein (a); peripheral artery disease
Rights: © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
RMID: 1000017878
DOI: 10.1161/JAHA.119.015355
Grant ID: http://purl.org/au-research/grants/nhmrc/1022752
http://purl.org/au-research/grants/nhmrc/1063476
Appears in Collections:Biochemistry publications

Files in This Item:
File Description SizeFormat 
hdl_125010.pdfPublished version631.42 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.